Monitor upcoming data presentations at AUA (May 15) and ISSVA (May 20) for clinical catalysts, and the BLA submission timeline for LMs. The stock is likely to trade on pipeline progress rather than quarterly financials.
Price Chart
Executive Summary
Protara Therapeutics reported Q1 2026 net loss of $17.8M ($0.31/sh), beating the $-0.36 consensus by ~14%. Cash stood at $177M, sufficient into 2028. The company intends to submit a BLA for TARA-002 in lymphatic malformations in 2H 2027 and expects to complete ADVANCED-2 enrollment in 2H 2026. The earnings beat is positive, but widening losses and the lack of revenue limit the impact.
Key Financial Metrics
Key Facts
- Net loss Q1 2026: $17.8M vs $11.9M in Q1 2025
- EPS: -$0.31 vs consensus -$0.36 (13.9% beat)
- Cash and investments: $177.4M as of March 31, 2026
- BLA submission for TARA-002 in LMs targeted for 2H 2027
- ADVANCED-2 trial enrollment completion expected in 2H 2026
- R&D expenses increased to $13.6M from $9.1M YoY
Financial Impact
EPS beat of ~14% but net loss widened by 49% YoY; no revenue stream
Risk Factors
- Clinical trial delays or negative data
- Cash burn rate increasing with trial expansion
- Dilution risk from potential future equity offerings
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-055462 |
| Document: ea0288581-8k_protara.htm | 0001213900-26-055462 |
| Document: 0001213900-26-055462-index-headers.html | 0001213900-26-055462 |
| Document: 0001213900-26-055462-index.html | 0001213900-26-055462 |
| Document: 0001213900-26-055462.txt | 0001213900-26-055462 |
| 8-K Data (Synthetic) | 0001213900-26-055462 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 11, 2026 7w ago | 8-K | $3.91 $3.83 | ▼ −2.05% | ▼ −0.99% | $2.70 (−30.95%) |
Aug 11, 2026 7w ago | Press Release | $3.91 $3.83 | ▼ −2.05% | ▼ −0.99% | $2.70 (−30.95%) |
Jun 29, 2026 13w ago | 8-K | $3.82 $4.04 | ▲ +5.76% | ▲ +6.79% | $2.70 (−29.32%) |
May 26, 2026 18w ago | EFFECT | $4.80 $4.06 | ▲ +15.52% | ▲ +13.57% | $2.70 (+43.75%) |
May 15, 2026 20w ago | Press Release | $5.10 $3.94 | ▼ −22.75% | ▼ −24.86% | $2.70 (−47.06%) |
May 13, 2026 20w ago | 8-K | $5.20 $3.65 | ▼ −29.81% | ▼ −29.19% | $2.70 (−48.08%) |
May 13, 2026 20w ago | Press Release | $5.20 $3.65 | ▼ −29.81% | ▼ −29.19% | $2.70 (−48.08%) |
Apr 28, 2026 22w ago | DEFA14A | $5.17 $4.75 | ▼ −8.12% | ▼ −14.17% | $2.70 (−47.78%) |
Mar 10, 2026 29w ago | Press Release | $5.71 $5.22 | ▼ −8.58% | ▼ −8.43% | $2.70 (−52.71%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access